NMDAR-autoantibodies in patients with affective disorders: a systemic review
|
Full Text:
Subscribers Only
|
Suggested citation:
Evtushenko UI, Shmukler AB. [NMDAR-autoantibodies in patients with affective disorders: a systemic review]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2025;(3):87-94. Russian
In order to establish a potential relationship between the detection of elevated titer and the frequency of mood disorders, as well as the expediency of its determination in the framework of the differential diagnosis of true affective disorders and affective manifestations of anti-NMDAR encephalitis (ANMDARE), a systematic review of the literature was conducted. The selection of publications was carried out in accordance with the PRISMA methodology: 9 publications were included in the review. In only a limited number of cases, the positive titer of autoantibodies in cerebrospinal fluid (CSF)/serum indicated the diagnosis of affective disorders at the onset of ANMDAR rather than true mood disorders. The features and dynamics of the clinical picture of the disease remain the most significant in the differential diagnosis of "primary" affective disorders and symptomatic manifestations of ANMDARE. Further large-scale studies with comparable control groups and cohorts of patients with other psychiatric disorders are required to determine the overall level of seropositivity in patients with primary affective spectrum disorders.
Keywords encephalitis; autoantibodies; N-methyl-D-aspartate receptors; cerebrospinal fluid; serum; mood disorders; affective disorders; bipolar disorder; depression; mania
1. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25–36. DOI: 10.1002/ana.21050 2. Lynch DR, Rattelle A, Dong YN, et al. Anti-NMDA receptor encephalitis: Clinical features and basic mechanisms. Advances in Pharmacology. 2018;82:235–60. DOI: 10.1016/bs.apha.2017.08.005 3. Gong X, Wang N, Zhu H, et al. Anti-NMDAR antibodies, the blood–brain barrier, and anti-NMDAR encephalitis. Frontiers in Neurology. 2023;14:1283511. DOI: 10.3389/fneur.2023.1283511 4. Wang W, Zhang L, Chi X-S, et al. Psychiatric symptoms of patients with anti-NMDA receptor encephalitis. Frontiers in Neurology. 2020;10:1330. DOI: 10.3389/fneur.2019.01330 5. Kawaia H, Takakia M, Sakamotoa Sh, et al. Anti-NMDA-receptor antibody in initial diagnosis of mood disorder. European Neuropsychopharmacology. 2019;29:1041–50. DOI: 10.1016/j.euroneuro.2019.07.137 6. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology. 2016;4:391–404. DOI: 10.1016/S1474-4422(15)00401-9 7. Ferensztajn-Rochowiaka E, Kaczmarekb M, Wójcickac M, et al. Glutamate-related antibodies and peripheral insulin-like growth factor in bipolar disorder and lithium prophylaxis. Neuropsychobiology. 2019;77:49–56. DOI: 10.1159/000493740 8. Flores-Sotoa ME, Chaparro-Huertaa V, Escoto-Delgadillo M, et al. Structure and function of NMDA-type glutamate receptor subunits. Neurología. 2012;27:301–10. DOI: 10.1016/j.nrl.2011.10.014 9. Loureiro CM, Corsi-Zuell F, Fachim HA, et al. Plasma prevalence of anti-N-methyl-d-aspartate receptor IgG antibodies in early stages of psychosis. Cien Saude Colet. 2021;26:1084–94. DOI: 10.1590/1413-81232021263.07552019 10. Arino H, Coutinho E, Pollak ThA, et al. Real-world experience of assessing antibodies against the N-methyl-D-aspartate receptor (NMDAR-IgG) in psychiatric patients. A retrospective single-centre study. Brain, Behaviour, and Immunity. 2021;98:330–6. DOI: 10.1016/j.bbi.2021.08.233 11. Espinola-Nadurille M, Restrepo-Martínez M, Bayliss L, et al. Neuropsychiatric phenotypes of anti-NMDAR encephalitis: a prospective study. Psychological Medicine. 2023;53:4266–74. DOI: 10.1017/S0033291722001027 12. Spektor VA. [The role of antibodies to NMDA-receptors in the development of affective disorders]. Sotsial'naya i klinicheskaya psikhiatriya [Social and clinical psychiatry]. 2023;33(2):82–90. (In Russ.) 13. Lejuste F, Thomas L, Desestret GPV, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neuroimmunol. Neuroinflammat. 2016;3:e280. DOI: 10.1212/NXI.0000000000000280 14. Kruse JL, Lapid MI, Lennon VA, et al. Psychiatric autoimmunity: N-methyl-D-aspartate receptor IgG and beyond. Psychosomatics. 2015;56:227–41. DOI: 10.1016/j.psym.2015.01.003 15. Dickerson F, Stallings C, Vaughan C, et al. Antibodies to the glutamate receptor in mania. Bipolar Disorders. 2012;14:547–553. DOI: 10.1111/j.1399-5618.2012.01028.x 16. Al-Diwani A, Handel A, Townsend L, et al. The psychopathology of NMDAR-antibody encephalitis in adults: A systematic review and phenotypic analysis of individual patient data. The Lancet Psychiatry. 2019;6(3):235–46. DOI: 10.1016/S2215-0366(19)30001-x 17. Salnikova LI, Kiryanova EM. [The clinical relevance of serum versus CSF NMDAR autoantibodies]. Sotsial'naya i klinicheskaya psikhiatriya [Social and clinical psychiatry]. 2023;33(2):91–9. (In Russ.) 18. Cullen AE, Palmer-Cooper EC, Hardwick M, et al. Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders: a meta-analysis of cross-sectional and case control studies. Lancet Psychiatry. 2021;8(2):109–20. DOI: 10.1016/S2215-0366(20)30432-6
Article Metrics
Metrics powered by PLOS ALM